cyrilzakka/clinical-trials huggingface dataset:
Long-term Study of TAK-875

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with TAK-875 in diabetic patients.


Eligibility Criteria:
Inclusion Criteria:

1. The participant is an outpatient.
2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
2. The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.
The Accuracy of Smartphone Pulse Oximetry in Patients Visiting an Outpatient Pulmonary Function Lab for a 6-Minute Walk Test

The primary aim of this research is to determine the accuracy of smartphone pulse oximeters in detecting blood oxygen saturations, episodes of desaturations, and heart rate by comparing results to a Masimo© hospital-grade pulse oximeter.


Eligibility Criteria:
Inclusion Criteria:

* Ambulatory
* 18 years and older
* Visiting the pulmonary function laboratory at Rush University Medical Center for a 6-minute walk test that agree to participate.

Exclusion Criteria:

* Under the age of 18 years
* High blood pressure above 180/90 mm Hg or pressure below 70/50 mm Hg
* Dizzy, lightheaded or have severe headaches at time of enrollment
* SpO2 at or below 85% on supplemental oxygen
* On oxygen greater than 4 liters per minute
* Gait issues that may result in a fall or patient walks with a walker and did not bring the device to this visit
Outcome After Arthroscopic Surgery in Patients Treated With PAO

The purpose of the study is to evaluate outcome after arthroscopy if the hip in patients previous treated with periacetabular osteotomy

It is well known the patients with developmental dysplasia of the hip beyond the bony malformation has intraarticular damage to labrum and chondral structures.

In DK, if the patients has persistent pain in the hip joint after PAO, they have been offered a hip arthroscopy, however we do not if their hip functions and pain improved by the surgery

The investigator aimed to make a short to middle-term followup study to see if the patients had benefits of the surgery.

Eligibility Criteria:
Inclusion Criteria:

* previous PAO and hip arthroscopy
* developmental dysplasia of the hip

Exclusion Criteria:

* calve legg perthes disease
* femoral osteotomy
Vital Sensor Monitors for CV19 Detection

This study will monitor physical bio-markers such as heart rate, respiratory rate, and temperature to detect potential COVID-19 infections.

The purpose of this research is to assess the accuracy of wearable sensors at detecting and monitoring COVID-19 infections. Our small, wearable sensor can get data on your respiration, body temperature, heart rate, and blood oxygen level, which may help physicians better identify if a respiratory condition is worsening overtime. If successful, our sensor could help healthcare professionals detect early symptoms of COVID-19 respiratory infection and monitor recovery and treat people before their condition worsens significantly.

Eligibility Criteria:
Inclusion Criteria:

* Adults aged 18 years old or over
* Recent (within 1 week) occupational or home exposure to a newly diagnosed COVID-19 infected individual
* Able and willing to give written consent and comply with study procedures

Exclusion Criteria:

* Inability to understand instructions and follow a three step command
* The subject is pregnant, nursing or planning a pregnancy
* Inability to provide written consent
* Past confirmed COVID-19 infection with resolution of symptoms
* Past confirmed COVID-19 active infection moderate or severe symptoms
HAptic Neurofeedback Design for Stroke

Interventional study with minimal risks and constraints, prospective, monocentric.

Many patients with stroke have a severe motor deficit in the upper limb impacting their independence. Electroencephalogram (EEG) Neurofeedback is a re-education technique that improves cerebral plasticity and motor gain in these people during the chronic phase of stroke. The visual feedback usually used tends to diminish the subject's attentional resources, while the proprioceptive feedbacks appear to be more effective on cortical excitability. Vibration feedback inducing movement illusion has been shown to be effective in healthy subjects, but has not been tested in people with stroke.

Eligibility Criteria:
Inclusion Criteria:

* Healthy Volunteers : Major (age greater than or equal to 18 years) and under 80 years; Free, informed and written consent signed by the volunteer; Absence of clinical neurological antecedents that can interact with the achievement of the motor task or with the EEG signal.
* Patients after stroke : Major (age greater than or equal to 18 years) and under 80 years;Ischemic or unilateral cerebral hemorrhagic hemorrhagic attack;Stroke dating back more than 6 months (considered as a delay where recovery of the upper limb to wait is less with conventional rehabilitation);Mild to severe upper limb deficiency: FMA-EU score ≤ 60; Free, informed and written consent signed by the patient or a member of his entourage (in the case of a patient able to understand the information and to express his / her consent but presenting motor difficulties leading to an invalid signature).

Exclusion Criteria:

* Healthy Volunteers : major persons subject to legal protection, persons deprived of their liberty
* Patients after stroke : Ischemic or hemorrhagic involvement of posterior fossa (brainstem, cerebellum);Complete motor deficiency of the upper limb (FMA-UE = 0);Epicritic and proprioceptive anesthesia;Understanding difficulties limiting participation in the study;Major persons subject to legal protection, persons deprived of their liberty
Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India

This study will define the substantial disease burden associated with viral hepatitis in India, and provide a foundation to understand the host and viral determinants of disease pathogenesis that may ultimately impact treatment decisions and outcome

The overall goal of this study is to correlate the host and viral genetics of patients infected with viral hepatitis with their clinical presentation. This study will provide the first nation-wide estimate of key host genetic polymorphisms associated with immune response, such as in the IL28B gene locus which has been associated with treatment outcomes in hepatitis C. Characterization of HCV and HBV viral genotypes and sub-types across different geographic regions will allow for an exploration of associations between host and viral genotypes. Another objective of this study is to identify co-morbid illness and metabolic factors that are associated with chronic liver disease due to viral hepatitis. Finally, this survey will explore patient awareness of their disease, risk factors for disease progression, and their treatment options

Eligibility Criteria:
Inclusion Criteria:

* Willing and able to provide written informed consent
* Male or female, age \>= 18
* Willing and able to comply with the visit procedure
* Prior diagnosis of chronic HCV infection or chronic HBV infection

Exclusion Criteria:

* History of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy
* History of bleeding disorder
* Blood loss requiring transfusion or \> 3 g/dL decrease in hemoglobin within 4 days of the visit
* Knowingly co-infected with HCV/HBV or with HIV
* Currently undergoing therapy for chronic hepatitis C or chronic hepatitis B
* Currently receiving treatment with any other investigational agent or device -- Enrolled in another clinical study evaluating a treatment or procedure
Impact of Bladder Underactivity on Treatment Outcomes of Laser Prostatectomy

The aim of this study was to evaluate an impact of preoperative bladder underactivity on treatment outcomes of photoselective vaporization of the prostate (PVP) or holmium laser enucleation of the prostate (HoLEP) in the treatment of benign prostatic obstruction, and to compare it between the two types of surgery for benign prostatic hyperplasia.


Eligibility Criteria:
Inclusion Criteria:

* patients in whom 12-month follow-up data were available

Exclusion Criteria:

* a previous diagnosis of urethral stricture
* prostate or bladder carcinoma
* neurogenic bladder disease
* a previous history of urological surgery
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

This is a prospective, multicenter, phase III study of Tucidinostat, Azacitidine combined with CHOP versus CHOP in patients with untreated peripheral T-cell lymphoma

Tucidinostat, a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. Azacytidine is a hypomethylating agent. The aim of this study is to compare the efficacy and safety of azacytidine, tucidinostat combined with CHOP regimen and classical CHOP regimen in the treatment of primary PTCL

Eligibility Criteria:
Inclusion Criteria:

* Patients with peripheral T-cell lymphoma confirmed by primary pathology;
* Age 18-70 years;
* ECOG performance status ≤ 2;
* Adequate bone marrow hematopoietic function: WBC \> 3.5 × 10\*9/L，ANC\>1.5 × 10\*9/L，HGB\>90g/L，PLT\>80 × 10\*9/L;
* Adequate organ function: cardiac function grade 0-2 (NYHA); SpO2 \> 88% (natural condition); ALT\<3UNL，TBil\<2ULN; SCr\>60ml/min/m2;
* Patients have signed the Informed Consent Form

Exclusion Criteria:

* ALK positive anaplastic T-cell lymphoma;
* NK / T cell lymphoma, nasal type;
* Uncontrolled active infection;
* Acute myocardial infarction or unstable angina pectoris within 6 months; uncontrolled hypertension, symptomatic arrhythmia, etc;
* Subjects who are known or suspected to be unable to comply with the study protocol;
* Pregnant or lactating women
Chronic Remote Ischemic Conditioning to Modify Post-MI Remodeling

During a heart attack, an artery carrying blood and oxygen to the heart becomes blocked, which causes damage to the heart muscle. When possible, a clot-busting drug is given or a procedure called angioplasty is performed soon after a heart attack starts, to open up the blocked artery and restore blood flow to the heart. While this can be an effective treatment to reduce permanent damage to the heart, patients can still experience heart failure afterwards. Consequently many patients require medications to support their heart after a heart attack. Recent research has shown a new technique called Remote Ischemic conditioning or RIC, is effective at protecting the heart muscle in a heart attack. RIC is produced simply by repeated inflation and deflation of a blood pressure cuff on an arm or leg to temporarily cut off and then restore blood flow to that limb. The investigators believe this triggers the release of molecular factors that protect heart muscle. In a recent study in humans, it reduced the amount of permanent damage to the heart muscle when applied before the angioplasty procedure. The investigators recent animal studies have shown that RIC may also help the heart muscle recover after a heart attack if applied everyday during the month after a heart attack, by preventing heart failure. This is important for two reasons: first, currently the investigators can only treat heart failure with medications, and second, some people have heart attacks but are not suitable to have angioplasty and so are at greater risk of heart failure. Daily RIC may provide an easy and effective new treatment to prevent heart failure after a heart attack. This application proposes a preliminary study in humans to see if daily RIC can help heart muscle recovery after a heart attack.


Eligibility Criteria:
Inclusion Criteria:

(i) Admitted for primary PCI for STEMI involving the LAD within 12 hours of onset of symptoms. STEMI will be defined as typical ECG changes (ST segment elevation ≥2mm in 2 or more precordial leads) associated with acute chest pain or an elevation of cardiac enzymes; (ii) Antegrade TIMI 0 or 1 prior to PCI; (iii) Age ≥18 years; (iv) Informed consent from patient or next of kin.

Exclusion Criteria:

(i) Known history of diabetes; (ii) Coronary anatomy warranting emergent coronary artery bypass graft surgery; (iii) Mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation); (iv) Need for hemodialysis; (v) Malignancy, HIV, or central nervous system disorder; (vi) Cardiopulmonary resuscitation \>15 min and compromised level of consciousness; (vii) Cardiogenic shock; (viii) Current participation in any research study involving investigational drugs or devices; (ix) Inability to safely undergo cMRI
Survivor Mom Companion Comparison Study

The overall goal of the SMC is to help reduce posttraumatic stress symptomology for pregnant persons with a history of trauma.

The study is a pilot randomized waitlist-controlled trial that examines the preliminary efficacy of the SMC for reducing PTSD symptomology as compared to a waitlist control group. Also, it aims to assess the feasibility and acceptability of the SMC. It examines how changes in the theorized mechanisms (emotion regulation, interpersonal sensitivity) mediate the relationship between the intervention and PTSD symptomology.

Eligibility Criteria:
Inclusion Criteria:

* English- or Spanish-speaking
* Currently pregnant or in the postpartum period
* Age 18 and older
* A history of trauma and PTSD
* Able to comprehend the study protocol and consent form and provide verbal consent and
* able to commit to a minimum of 4 weekly intervention sessions.

Exclusion Criteria:

* Non-English or non-Spanish-speaking,
* less than 18 years of age,
* those with psychotic conditions or developmental disabilities requiring guardianship,
* those with high-risk pregnancies necessitating extended bedrest or inpatient care, and
* those unable to commit to completing the intervention sessions.
Properties of Myocardial Microcirculation in Patients With Different Pathomorphological Substrates, Before and After Recanalization of Coronary Artery CTO

This study will evaluate the changes in myocardial microcirculatory parameters of the collateral donor artery after recanalization of coronary artery chronic total occlusion.

This study will include patients with chronic total occlusion (CTO) of one coronary artery who will undergo the recanalization of the CTO. Before the procedure, myocardial viability, ischemia, functional parameters of the collateral donor blood vessels, echocardiography, and quality of life will be assessed. After the recanalization, these parameters will be assessed again 24h and 6 months after the procedure.

Eligibility Criteria:
Inclusion Criteria:

* Patients over the age of 18 with signed informed consent to participate in the study
* Presence of one CTO on native coronary arteries (with TIMI 0 flow)
* Presence of clinical indication for attempting a PCI for CTO (at least one of the criteria present):

  1. Symptoms of typical stable angina
  2. Presence of inducible ischemia in the territory of the occluded artery
  3. Presence of viable myocardium in the territory of the occluded artery
* The diameter of the occluded artery ≥2.5mm

Exclusion Criteria:

* Acute coronary syndrome in the past month
* Existing contraindication for administration of dual antiplatelet therapy in the duration of 12 months
* Contraindications for implanting the drug-eluting stents
* Existence of 2 or more CTOs on native coronary arteries (with TIMI 0 flow)
* Severe tortuosity or calcifications of the coronary arteries
* Left ventricle aneurysm
* Previous coronary artery bay-pass graft or any other cardiac surgery
* Previous myocardial infarction in the coronary artery territory different from the CTO
* Ejection fraction of the left ventricle less than 30%
* Permanent atrial fibrillation
* Pregnancy
* Patients with known allergy to iodine contrast that cannot be controlled with medication
* Patients who are unable or unwilling to cooperate and come for check-up visits
* Life expectancy less than a year
* Hemorrhagic diathesis, coagulopathy, or rejection of blood transfusion
Validating Clinical Efficacy for Integrated Psychological Intervention for Obesity: Physical Therapy and Psychotherapy

This study is to develop an integrated therapy (physical therapy and psychotherapy) to treat cognitive distortion for body image. Then, validate its efficacy to make an improvement in both physical and mental health.


Eligibility Criteria:
Inclusion Criteria:

* BMI 25\~30
* The score over 68 in SIMS (The situational motivation scale)

Exclusion Criteria:

* Diagnosed in any chronic disease
* Trouble using smartphone
* Pregnant or planning to be pregnant
* Unable to be in the fMRI
* Limited to be involved in physical activities over 30 minutes
* already had an experience in liposuction
Feasibility of Technology-Based SSIP in Prostate Cancer Patients

The goal of this pilot study is to assess the perceived usability of a smartphone application called WINGS targeting psychosocial distress and well-being in prostate cancer patients and their social network. The main questions it aims to answer are:

* How do prostate cancer patients and their social network rate the usability of the technology-based social-support intervention program smartphone application?
* Do symptoms of prostate cancer patients improve after using the WINGS smartphone application?
* Does the burden of prostate cancer patients social network decrease after using the WINGS smartphone application? Participants will be asked to use the WINGS smartphone application over the period of eight to twelve weeks and fill in questionnaires before, during, and after this time.

There is still little knowledge about how smartphone apps can improve the quality of life in prostate cancer patients. Hence, the investigators are interested in finding out whether the simplified access to information and planning of activities increases the perceived social support in prostate cancer patients and ultimately improves their quality of life.

The duration of the study is approximately three months per participant. The WINGS smartphone application can be used from home and questionnaires can be completed online. Participants are therefore not required to be present at the University Hospital Basel during the entire course of the present study.

The investigators plan to recruit a total of 30 prostate cancer patients at the University Hospital Basel and 0-10 supporters (family members and friends) per prostate cancer patient. All study participants will have access to the regular treatment services of the University Hospital Basel.

Eligibility Criteria:
Inclusion Criteria:

* Able and willing to give written consent
* Male;
* ≥ 18 years of age;
* Sufficient knowledge of German language;
* Confirmed diagnosis of prostate carcinoma;
* Successfully completed prostatectomy with "Da Vinci®" method;
* Willingness to use the WINGS-IP1 Smartphone Application (technology-based SSIP);
* In possession of a smartphone on which the WINGS-IP1 Smartphone Application V1.0 can be installed (required operating systems: iOS 12.1 or newer, Android 7.0 or newer);
* Access to the Internet with smartphone;
* Ability to operate a smartphone;

Exclusion Criteria:

* Previous enrolment in the current investigation;
* Current diagnosis of severe mental disorder, namely bipolar disorder, schizophrenia, personality disorder;
* Simultaneous participation in any other clinical trial, hospital program, or psychosocial intervention targeting similar concepts (e.g., mental wellbeing, social support, sexuality, etc.);
* Receiving any current treatment for mental disorder (psychotherapy and/or medication) apart from already existing long-lasting therapies (≥ 6 months);
ATOMIC Mobile App to Increase Physical Activity (PA) Levels in Survivors of Childhood Cancer

Development and Usability Testing of the ATOMIC Mobile App to Increase Physical Activity (PA) Levels in Children, Adolescent and Young Adults (AYA) survivors of childhood cancer

The purpose of this program of research is to (1) determine the adaptations required of a pre-existing mobile fitness app to tailor it for childhood cancer survivors using a behavioral theory driven approach (Social Cognitive Theory) and (2) develop and evaluate the usability of the adapted mobile app using the Technology Assessment Model. The Technology Assessment Model (TAM), which theorizes the individuals' intentions to use information technology, is based on two driving factors: perceived usefulness and perceived ease of use. Future studies will evaluate the feasibility and effectiveness of this app.

Eligibility Criteria:
Inclusion Criteria:

* Children, adolescent and young adults (AYA) ages 10 to 30 years
* diagnosis with a pediatric cancer diagnosis that requires the treatment of anthracycline therapy
* Able to speak English fluently (App currently only in English at this time)

Exclusion Criteria:

* Pediatric cancer survivors who will not be treated with anthracycline therapy
* Unable to cooperate with interviewing
* Unable to understand the content of interviews
* Non-English speaking
A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3455 tablets in subjects with advanced malignancies.


Eligibility Criteria:
Inclusion Criteria:

* 1. ≥ 18 years old； Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; Life expectancy ≥12 weeks.

  2. Has IDH2 gene mutation will be selected preferentially. 3. The toxicity of radiotherapy or other antitumor therapy should return to grade 1.

  4. No pregnant or lactating women, all the participants should use contraceptives.

  5. Understood and signed an informed consent form. 6. Advanced/metastatic solid tumors or refractory/recurrent acute myeloid leukemia.

  7. At least one measurable lesion for solid tumors. 8. Adequate organ system function.

Exclusion Criteria:

* 1.Relapsed after bone marrow transplantation. 2.Has received systemic antitumor therapy or radiation therapy within 3 weeks before the first dose.

  3.Has participated in other clinical trial within four weeks before the first dose.

  4.Has multiple factors affecting oral medication. 5.Has uncontrolled, active systemic fungal, bacterial, or viral infections. 6.Poorly controlled hypertension. 7.Has serious cardiovascular disease. 8.Has drug abuse history that unable to abstain from or mental disorders. 9.Has active hepatitis B or C. 10.Have a history of immunodeficiency. 11.According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.

  12.Has central nervous system metastasis with the exception of glioma subjects. 13.Has severe life-threatening complication of leukemia, such as uncontrolled bleeding, hypoxia or shock pneumonia, and disseminated intravascular coagulation.

  14.Has central nervous system leukemia.